Tracers / [68Ga]HTK03149
[68Ga]HTK03149
Also written as [Ga-68]Ga-HTK03149
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting Lys-urea-Glu (urea-based) small-molecule ligand
- Target / mechanism
- PSMA (prostate-specific membrane antigen) targeting via Lys-urea-Glu pharmacophore PMID 36168623
- Clinical application
- PSMA-targeted radioligand therapy of prostate cancer (preclinical, proposed for clinical translation) PMID 36168623
- Theranostic pair
- <a href="/tracers/lu177-htk03149/">lu177-htk03149</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | HPLC | — | — | HTK03149 | 36168623 2022 Theranostics |
Need this precursor?We can point you to suppliers for [68Ga]HTK03149, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36168623. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36168623: 'HTK03161, HTK03149 and HTK03189A/B were obtained by replacing Glu in HTK03041'.